Bank of New York Mellon
RLAY icon

Bank of New York Mellon’s Relay Therapeutics RLAY Stock Holding History

Bank of New York Mellon’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.66M Buy
462,756
+79,836
+21% +$1.16M ﹤0.01% 2105
2026
Q1 		$3.81M Buy
382,920
+4,217
+1% +$37.7K ﹤0.01% 2466
2025
Q4 		$3.2M Buy
378,703
+7,125
+2% +$50.8K ﹤0.01% 2581
2025
Q3 		$1.94M Buy
371,578
+13,207
+4% +$50.4K ﹤0.01% 2821
2025
Q2 		$1.24M Buy
358,371
+28,466
+9% +$84.7K ﹤0.01% 3005
2025
Q1 		$864K Buy
329,905
+1,008
+0.3% +$3.95K ﹤0.01% 3148
2024
Q4 		$1.36M Buy
328,897
+50,190
+18% +$273K ﹤0.01% 2958
2024
Q3 		$1.97M Sell
278,707
-75,960
-21% -$567K ﹤0.01% 2749
2024
Q2 		$2.31M Buy
354,667
+48,219
+16% +$329K ﹤0.01% 2719
2024
Q1 		$2.54M Sell
306,448
-15,613
-5% -$152K ﹤0.01% 2644
2023
Q4 		$3.55M Sell
322,061
-459
-0.1% -$3.87K ﹤0.01% 2539
2023
Q3 		$2.71M Buy
322,520
+759
+0.2% +$8.16K ﹤0.01% 2637
2023
Q2 		$4.04M Sell
321,761
-54,240
-14% -$675K ﹤0.01% 2439
2023
Q1 		$6.19M Sell
376,001
-12,484
-3% -$224K ﹤0.01% 2184
2022
Q4 		$5.8M Buy
388,485
+46,233
+14% +$885K ﹤0.01% 2254
2022
Q3 		$7.66M Buy
342,252
+44,636
+15% +$979K ﹤0.01% 2061
2022
Q2 		$4.99M Buy
297,616
+10,730
+4% +$230K ﹤0.01% 2302
2022
Q1 		$8.59M Buy
286,886
+5,958
+2% +$145K ﹤0.01% 2152
2021
Q4 		$8.63M Buy
280,928
+46,046
+20% +$1.46M ﹤0.01% 2182
2021
Q3 		$7.41M Buy
234,882
+67,509
+40% +$2.27M ﹤0.01% 2287
2021
Q2 		$6.12M Buy
167,373
+28,508
+21% +$939K ﹤0.01% 2391
2021
Q1 		$4.8M Buy
138,865
+23,011
+20% +$999K ﹤0.01% 2459
2020
Q4 		$4.81M Buy
115,854
+26,801
+30% +$1.21M ﹤0.01% 2377
2020
Q3 		$3.79M Buy
+89,053
New +$3.4M ﹤0.01% 2361

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Bank of New York Mellon's RLAY Position: Q2 2026 in Review

Bank of New York Mellon increased its Relay Therapeutics (RLAY) stake by 21% in Q2 2026, buying an estimated $1.16M and bringing the position to 462,756 shares worth $8.66M. The position accounts for ﹤0.01% of the portfolio, ranked #2105.

Bank of New York Mellon first reported a position in RLAY in Q3 2020 and has held it in 24 quarters since. 258 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Bank of New York Mellon held 462,756 shares of Relay Therapeutics worth $8.66M as of Q2 2026.
  • Bank of New York Mellon bought 79,836 Relay Therapeutics shares in Q2 2026, an estimated $1.16M.
  • Relay Therapeutics made up ﹤0.01% of Bank of New York Mellon's portfolio in Q2 2026, its #2105 holding.
  • Bank of New York Mellon first reported a position in Relay Therapeutics in Q3 2020 and has held it in 24 quarters since.
  • 258 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Bank of New York Mellon's 13F filing for Q2 2026, filed 6 Aug 2026.